在患有STEMI和多血管疾病的患者中完全重血管化的时间:系统性审查和元分析
Giuseppe Panuccio1, Nadia Salerno1, Salvatore De Rosa1
1Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
对于ST段升高心肌梗塞 (STEMI) 患有多血管冠状动脉疾病 (MVD) 的患者,立即完整的再血管化显示出类似的整体结果,但与分阶段再血管化相比,心血管死亡风险更高. 建议进行个性化治疗.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 临床试验 临床试验
背景情况:
- 多血管冠状动脉疾病 (MVD) 影响大约一半的ST段升高心肌梗塞 (STEMI) 患者.
- 在MVD的STEMI中,最佳的重血管化策略仍然是积极研究的领域.
研究的目的:
- 在MVD的STEMI患者中,量化比较单个阶段的即时完全重血管化与延迟阶段的完全重血管化.
- 评估重血管化时间对临床结果的影响.
主要方法:
- 对所有相关研究进行系统审查和元分析.
- 纳入标准:患有MVD的STEMI患者.
- 主要终点:综合所有死因,心肌梗塞和重复血管化.
- 二级终点:心血管死亡,急性损伤和严重出血.
主要成果:
- 分析了8项涉及2256名患者的研究.
- 立即和分阶段完全重血管化之间的初级复合终点没有显著差异 (RR 0.95;95% CI 0.71-1.27;p = 0.74).
- 随着即时完整的再血管化 (5.0%对2.6%;RR 0.39;95% CI 0.25-0.62;p < 0.01) 观察到较高的心血管死亡率.
- 超回归表明与药物释放支架 (DES) 使用有显著的相互作用.
结论:
- 对于单阶段的即时和延迟阶段的完整重血管化策略,观察到类似的临床结果.
- 立即完整的再血管可能与心血管死亡风险增加有关.
- 在等待进一步的试验数据之前,建议进行个性化血管再循环,考虑临床环境,患者因素和后勤因素.
更多相关视频
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.0K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
相关概念视频
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...